Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1Phase 1 1

Status

Withdrawn 2Active not recruiting 1

Sponsor Class

OTHER 2FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 7Genitourinary 3Breast 3CNS 2Tumor-Agnostic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Prostatic Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × copanlisib × Genitourinary × Clear all
NCT05687721 2025-06-15

Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer

VA Office of Research and Development

Phase 1/2 Withdrawn
Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT04253262 2025-05-04

A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

Brown University

Phase 1/2 Active not recruiting
13 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06218667 2024-10-31

A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡